Autologous cultured keratinocyte cell — Competitive Intelligence Brief

Autologous cultured keratinocyte cell (Autologous cultured keratinocyte cell) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy. Area: Dermatology.

phase 3 Cell therapy Dermatology Small molecule

Target snapshot

Autologous cultured keratinocyte cell (Autologous cultured keratinocyte cell) — Biosolution Co., Ltd.. Autologous cultured keratinocytes are patient-derived skin cells grown in vitro and applied topically or as a graft to promote wound healing and tissue regeneration.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Autologous cultured keratinocyte cell TARGET	Autologous cultured keratinocyte cell	Biosolution Co., Ltd.	phase 3	Cell therapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
Fibroblasts and keratinocytes	Fibroblasts and keratinocytes	Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus	marketed	Cell therapy
Stem Cell	Stem Cell	Neurogen Brain and Spine Institute	marketed	Cell therapy
Mesenchymal Stem Cells (MSCs)	Mesenchymal Stem Cells (MSCs)	The Cleveland Clinic	marketed	Cell therapy
Licartin and CIK	Licartin and CIK	Tianjin Medical University Cancer Institute and Hospital	marketed	Monoclonal antibody (Licartin); Adoptive cell therapy (CIK)	HAb18G/CD147 antigen (Licartin); Multiple (CIK cells)
3ml-Rejuvinex	3ml-Rejuvinex	Seoul National University Bundang Hospital	marketed	Autologous cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy class)

1. Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León · 2 drugs in this class
2. Bone Therapeutics S.A · 1 drug in this class
3. DiscGenics, Inc. · 1 drug in this class
4. Celavie Bioscences, LLC · 1 drug in this class
5. China Spinal Cord Injury Network · 1 drug in this class
6. City of Hope Medical Center · 1 drug in this class
7. Brainstorm-Cell Therapeutics · 1 drug in this class
8. Dr. Grant M. Pagdin · 1 drug in this class
9. FDA Office of Orphan Products Development · 1 drug in this class
10. Biosolution Co., Ltd. · 1 drug in this class